Xtant Medical (XTNT) analyst forecast and price target
Analyst forecast
Consensus of 2 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| BTIG | Maintained | Buy | $1.00 | May 13, 2026 |
| BTIG | Maintained | Buy | $1.00 from $1.50 | Mar 31, 2026 |
| BTIG | Maintained | Buy | $1.50 from $2.00 | Nov 11, 2025 |
| BTIG | Maintained | Buy | $3.00 from $2.00 | May 16, 2024 |
| BTIG | Initiated Coverage | Buy | $2.00 | Dec 5, 2023 |
| Craig-Hallum | Maintained | Buy | $1.20 from $1.00 | Jul 11, 2023 |
Frequently asked questions
Is XTNT a buy, sell, or hold?
Analysts covering Xtant Medical currently average a Buy rating: 2 buy, 0 hold and 0 sell, from 2 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on XTNT?
On May 13, 2026, BTIG maintained Xtant Medical at Buy with a price target of $1.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.